Compare Stocks: FULC, MLTX, CRVS, and MNKD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$11.87 +2.2%	$13.72	$6.39 ▼ $26.95	$977.48M	0.87	1.12 million shs	1.21 million shs
FULC Fulcrum Therapeutics	$3.72 -0.5%	$3.79	$2.83 ▼ $15.74	$285.35M	2.59	1.36 million shs	901,247 shs
MLTX MoonLake Immunotherapeutics	$11.56 -4.0%	$15.69	$5.95 ▼ $23.29	$1.02B	1.04	1.62 million shs	1.52 million shs
MNKD MannKind	$3.35 +0.3%	$3.88	$2.23 ▼ $6.51	$1.07B	1.1	4.07 million shs	2.08 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	0.00%	-7.48%	-17.94%	-19.75%	+57.24%
FULC Fulcrum Therapeutics	0.00%	-0.53%	-2.86%	+0.27%	-57.69%
MLTX MoonLake Immunotherapeutics	0.00%	-2.82%	-19.68%	-39.53%	-80.58%
MNKD MannKind	0.00%	-5.65%	-15.44%	-21.23%	-39.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$11.87 +2.2%	$13.72	$6.39 ▼ $26.95	$977.48M	0.87	1.12 million shs	1.21 million shs
FULC Fulcrum Therapeutics	$3.72 -0.5%	$3.79	$2.83 ▼ $15.74	$285.35M	2.59	1.36 million shs	901,247 shs
MLTX MoonLake Immunotherapeutics	$11.56 -4.0%	$15.69	$5.95 ▼ $23.29	$1.02B	1.04	1.62 million shs	1.52 million shs
MNKD MannKind	$3.35 +0.3%	$3.88	$2.23 ▼ $6.51	$1.07B	1.1	4.07 million shs	2.08 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	0.00%	-7.48%	-17.94%	-19.75%	+57.24%
FULC Fulcrum Therapeutics	0.00%	-0.53%	-2.86%	+0.27%	-57.69%
MLTX MoonLake Immunotherapeutics	0.00%	-2.82%	-19.68%	-39.53%	-80.58%
MNKD MannKind	0.00%	-5.65%	-15.44%	-21.23%	-39.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVS Corvus Pharmaceuticals	2.88	Moderate Buy	$33.33	180.82% Upside
FULC Fulcrum Therapeutics	1.75	Reduce	$8.20	120.43% Upside
MLTX MoonLake Immunotherapeutics	2.44	Hold	$24.57	112.56% Upside
MNKD MannKind	2.50	Moderate Buy	$8.34	149.07% Upside

Current Analyst Ratings Breakdown

Latest FULC, MLTX, CRVS, and MNKD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	CRVS Corvus Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/16/2026	MLTX MoonLake Immunotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/11/2026	MNKD MannKind	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
9/3/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/21/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
8/7/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/6/2026	MNKD MannKind	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$14.00 ➝ $13.00
8/5/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/30/2026	MNKD MannKind	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $14.00
7/30/2026	CRVS Corvus Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.13 per share	91.67	$0.73 per share	N/A
FULC Fulcrum Therapeutics	$80M	3.55	N/A	N/A	$6.45 per share	0.58
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A
MNKD MannKind	$348.97M	3.09	$0.06 per share	53.98	($0.17) per share	-19.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.61	N/A	N/A	N/A	N/A	-36.15%	-33.62%	11/3/2026 (Estimated)
FULC Fulcrum Therapeutics	-$74.88M	-$1.21	N/A	N/A	N/A	N/A	-25.38%	-24.15%	10/29/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.13	N/A	N/A	N/A	-11.08%	-11.21%	-6.31%	11/4/2026 (Estimated)

Latest FULC, MLTX, CRVS, and MNKD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A
8/6/2026	Q2 2026	CRVS Corvus Pharmaceuticals	-$0.1591	-$0.19	-$0.0309	-$0.19	N/A	N/A
8/5/2026	Q2 2026	MNKD MannKind	-$0.0075	-$0.01	-$0.0025	-$0.06	$108.08 million	$109.37 million
7/30/2026	Q2 2026	FULC Fulcrum Therapeutics	-$0.2433	-$0.34	-$0.0967	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVS Corvus Pharmaceuticals	N/A	16.16	16.16
FULC Fulcrum Therapeutics	N/A	31.35	31.35
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56
MNKD MannKind	N/A	1.72	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVS Corvus Pharmaceuticals	46.64%
FULC Fulcrum Therapeutics	89.83%
MLTX MoonLake Immunotherapeutics	93.85%
MNKD MannKind	49.55%

Insider Ownership

Company	Insider Ownership
CRVS Corvus Pharmaceuticals	19.70%
FULC Fulcrum Therapeutics	7.30%
MLTX MoonLake Immunotherapeutics	10.40%
MNKD MannKind	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVS Corvus Pharmaceuticals	37	84.12 million	67.55 million	Optionable
FULC Fulcrum Therapeutics	55	76.30 million	70.73 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable
MNKD MannKind	592	321.54 million	313.18 million	Optionable

FULC, MLTX, CRVS, and MNKD Headlines

Recent News About These Companies

Insider Selling: MannKind (NASDAQ:MNKD) Director Sells $128,477.79 in Stock

9 minutes ago | marketbeat.com

Cours MannKind Corporation Boerse Muenchen

September 24, 2026 | zonebourse.comZ

MannKind (NASDAQ:MNKD) Trading Down 3.6% - Time to Sell?

September 24, 2026 | americanbankingnews.com

H.C. Wainwright Keeps Their Buy Rating on MannKind (MNKD)

September 23, 2026 | theglobeandmail.com

MannKind (NASDAQ:MNKD) Trading Down 3.6% - Should You Sell?

September 22, 2026 | marketbeat.com

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

September 17, 2026 | marketbeat.com

MannKind Corporation (NASDAQ:MNKD) Receives Average Rating of "Moderate Buy" from Analysts

September 17, 2026 | americanbankingnews.com

MannKind Corporation (NASDAQ:MNKD) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 17, 2026 | marketbeat.com

413,062 Shares in MannKind Corporation $MNKD Purchased by Squarepoint Ops LLC

September 16, 2026 | marketbeat.com

MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses

September 15, 2026 | insidermonkey.com

MannKind出席H.C. Wainwright年会：新品上市提振业务前景

September 15, 2026 | cn.investing.com

MannKind op H.C. Wainwright-conferentie: nieuwe lanceringen verbeteren vooruitzichten

September 15, 2026 | nl.investing.com

MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses

September 15, 2026 | finance.yahoo.com

MannKind (NASDAQ:MNKD) Director Sells 33,558 Shares of Stock

September 15, 2026 | insidertrades.com

Steven Binder Sells 33,558 Shares of MannKind (NASDAQ:MNKD) Stock

September 14, 2026 | marketbeat.com

Cantor Fitzgerald Keeps Their Buy Rating on MannKind (MNKD)

September 12, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and MannKind (MNKD)

September 11, 2026 | theglobeandmail.com

MannKind's (MNKD) Overweight Rating Reiterated at Cantor Fitzgerald

September 11, 2026 | marketbeat.com

MannKind inks obesity deal with Rose Pharma

September 9, 2026 | thepharmaletter.comT

MannKind, Rose Pharma Sign Deal to Develop Weight-Management Drug

September 9, 2026 | finance.yahoo.com

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

September 9, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC, MLTX, CRVS, and MNKD Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

$11.87 +0.25 (+2.15%)

Closing price 04:00 PM Eastern

Extended Trading

$12.06 +0.19 (+1.59%)

As of 07:30 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Fulcrum Therapeutics NASDAQ:FULC

$3.72 -0.02 (-0.53%)

Closing price 04:00 PM Eastern

Extended Trading

$3.72 +0.00 (+0.13%)

As of 06:15 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

MoonLake Immunotherapeutics NASDAQ:MLTX

$11.56 -0.48 (-3.99%)

Closing price 04:00 PM Eastern

Extended Trading

$11.62 +0.06 (+0.54%)

As of 07:50 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

MannKind NASDAQ:MNKD

$3.35 +0.01 (+0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$3.36 +0.01 (+0.39%)

As of 07:56 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FULC, MLTX, CRVS, and MNKD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FULC, MLTX, CRVS, and MNKD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FULC, MLTX, CRVS, and MNKD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC, MLTX, CRVS, and MNKD Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

Fulcrum Therapeutics NASDAQ:FULC

MoonLake Immunotherapeutics NASDAQ:MLTX

MannKind NASDAQ:MNKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FULC, MLTX, CRVS, and MNKD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FULC, MLTX, CRVS, and MNKD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FULC, MLTX, CRVS, and MNKD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC, MLTX, CRVS, and MNKD Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

Fulcrum Therapeutics NASDAQ:FULC

MoonLake Immunotherapeutics NASDAQ:MLTX

MannKind NASDAQ:MNKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools